Gene polymorphisms in association with emerging cardiovascular risk markers in adult women

BMC Medical Genetics

Volumn 11, Issue 1, 2010, Pages

  Fan, Amy Z ^a   Yesupriya, Ajay ^a   Chang, Man Huei ^a   House, Meaghan ^b   Fang, Jing ^a   Ned, Renée ^a   Hayes, Donald ^a   Dowling, Nicole F ^a   Mokdad, Ali H ^c  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; G PROTEIN COUPLED RECEPTOR KINASE 2; HOMOCYSTEINE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; URIC ACID; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE MARKER; DRUG USE; EDUCATIONAL STATUS; ETHNICITY; FEMALE; FIBRINOGEN BLOOD LEVEL; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HUMAN; LIFESTYLE; MENOPAUSE; PROTEIN BLOOD LEVEL; RACE DIFFERENCE; AGED; BLOOD; CARDIOVASCULAR DISEASE; DEMOGRAPHY; GENETICS; GENOTYPE; MIDDLE AGED; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DEMOGRAPHY; FEMALE; FIBRINOGEN; GENOTYPE; HOMOCYSTEINE; HUMANS; LINEAR MODELS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; URIC ACID;

EID: 77249162816     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-11-6     Document Type: Article

References (63)

1. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell CJ, Roger V, Rumsfeld J, Sorlie P, Steinberger J, Thom T, Wasserthiel-Smoller S, Hong Y. Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007, 115(5):e69-171. 10.1161/CIRCULATIONAHA.106.179918, 17194875.
2. National Center for Health Statistics Health, United States, 2008. With Special Features of the Health of Young Adults. 2008, Hyattsville, MD: Centers for Disease Control and Prevention, National Center for Health Statistics., http://www.cdc.gov/nchs/data/hus/hus08.pdf
3. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA 2003, 290(7):932-940. 10.1001/jama.290.7.932, 12928471.
4. Gillum RF, Makuc DM. Serum albumin, coronary heart disease, and death. Am Heart J 1992, 123(2):507-513. 10.1016/0002-8703(92)90667-K, 1736588.
5. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH, Heimovitz H, Cohen HJ, Wallace R. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999, 106(5):506-512. 10.1016/S0002-9343(99)00066-2, 10335721.
6. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998, 98(8):731-733.
7. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336(14):973-979. 10.1056/NEJM199704033361401, 9077376.
8. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998, 97(5):425-428.
9. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342(12):836-843. 10.1056/NEJM200003233421202, 10733371.
10. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997, 95(7):1777-1782.
11. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999, 99(2):237-242.
12. Tunstall-Pedoe H, Woodward M, Tavendale R, A'Brook R, McCluskey MK. Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish Heart Health Study: cohort study. BMJ 1997, 315(7110):722-729. 2127508, 9314758.
13. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996, 144(6):537-547.
14. Rosenson RS, Koenig W. Utility of inflammatory markers in the management of coronary artery disease. Am J Cardiol 2003, 92(1A):10i-18i. 10.1016/S0002-9149(03)00504-6, 12867250.
15. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350(14):1387-1397. 10.1056/NEJMoa032804, 15070788.
16. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004, 109(21 Suppl 1):II2-10.
17. Gagliardi AC, Miname MH, Santos RD. Uric acid: A marker of increased cardiovascular risk. Atherosclerosis 2009, 202(1):11-17. 10.1016/j.atherosclerosis.2008.05.022, 18585721.
18. Moat SJ. Plasma total homocysteine: instigator or indicator of cardiovascular disease?. Ann Clin Biochem 2008, 45(Pt 4):345-348. 10.1258/acb.2008.008053, 18583617.
19. Milani RV, Lavie CJ. Homocysteine: the Rubik's cube of cardiovascular risk factors. Mayo Clin Proc 2008, 83(11):1200-1202. 10.4065/83.11.1200, 18990317.
20. Hozawa A, Folsom AR, Ibrahim H, Javier Nieto F, Rosamond WD, Shahar E. Serum uric acid and risk of ischemic stroke: the ARIC Study. Atherosclerosis 2006, 187(2):401-407. 10.1016/j.atherosclerosis.2005.09.020, 16239005.
21. Leyva F, Anker S, Swan JW, Godsland IF, Wingrove CS, Chua TP, Stevenson JC, Coats AJ. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997, 18(5):858-865.
22. Malinow MR, Levenson J, Giral P, Nieto FJ, Razavian M, Segond P, Simon A. Role of blood pressure, uric acid, and hemorheological parameters on plasma homocyst(e)ine concentration. Atherosclerosis 1995, 114(2):175-183. 10.1016/0021-9150(94)05481-W, 7605386.
23. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005, 16(12):3553-3562. 10.1681/ASN.2005050572, 16251237.
24. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 2005, 25(1):39-42. 10.1016/j.semnephrol.2004.09.007, 15660333.
25. Cambien F, Tiret L. Genetics of cardiovascular diseases: from single mutations to the whole genome. Circulation 2007, 116(15):1714-1724. 10.1161/CIRCULATIONAHA.106.661751, 17923582.
26. Chang MH, Lindegren ML, Butler MA, Chanock SJ, Dowling NF, Gallagher M, Moonesinghe R, Moore CA, Ned RM, Reichler MR, Sanders CL, Welch R, Yesupriya A, Khoury MJ. Prevalence in the United States of selected candidate gene variants: Third National Health and Nutrition Examination Survey, 1991-1994. Am J Epidemiol 2009, 169(1):54-66. 10.1093/aje/kwn286, 2638878, 18936436.
27. Kitsios G, Zintzaras E. Genetic variation associated with ischemic heart failure: a HuGE review and meta-analysis. Am J Epidemiol 2007, 166(6):619-633. 10.1093/aje/kwm129, 17644825.
28. Drenos F, Whittaker JC, Humphries SE. The use of meta-analysis risk estimates for candidate genes in combination to predict coronary heart disease risk. Annals of human genetics 2007, 71(Pt 5):611-619. 10.1111/j.1469-1809.2007.00359.x, 17403027.
29. Zintzaras E, Zdoukopoulos N. A field synopsis and meta-analysis of genetic association studies in peripheral arterial disease: The CUMAGAS-PAD database. Am J Epidemiol 2009, 170(1):1-11. 10.1093/aje/kwp094, 19435865.
30. Masuo K, Katsuya T, Fu Y, Rakugi H, Ogihara T, Tuck ML. Beta2- and beta3-adrenergic receptor polymorphisms are related to the onset of weight gain and blood pressure elevation over 5 years. Circulation 2005, 111(25):3429-3434. 10.1161/CIRCULATIONAHA.104.519652, 15956122.
31. Balistreri CR, Colonna-Romano G, Lio D, Candore G, Caruso C. TLR4 polymorphisms and ageing: implications for the pathophysiology of age-related diseases. J Clin Immunol 2009, 29(4):406-415. 10.1007/s10875-009-9297-5, 19459036.
32. Lawlor DA, Harbord RM, Timpson NJ, Lowe GD, Rumley A, Gaunt TR, Baker I, Yarnell JW, Kivimaki M, Kumari M, Norman PE, Jamrozik K, Hankey GJ, Almeida OP, Flicker L, Warrington N, Marmot MG, Ben-Shlomo Y, Palmer LJ, Day IN, Ebrahim S, Smith GD. The association of C-reactive protein and CRP genotype with coronary heart disease: findings from five studies with 4,610 cases amongst 18,637 participants. PLoS One 2008, 3(8):e3011. 10.1371/journal.pone.0003011, 2507759, 18714384.
33. Haider DG, Leuchten N, Schaller G, Gouya G, Kolodjaschna J, Schmetterer L, Kapiotis S, Wolzt M. C-reactive protein is expressed and secreted by peripheral blood mononuclear cells. Clin Exp Immunol 2006, 146(3):533-539. 10.1111/j.1365-2249.2006.03224.x, 1810406, 17100775.
34. Dedoussis GV, Panagiotakos DB, Pitsavos C, Chrysohoou C, Skoumas J, Choumerianou D, Stefanadis C. An association between the methylenetetrahydrofolate reductase (MTHFR) C677T mutation and inflammation markers related to cardiovascular disease. Int J Cardiol 2005, 100(3):409-414. 10.1016/j.ijcard.2004.08.038, 15837084.
35. Ridker PM, Pare G, Parker A, Zee RY, Danik JS, Buring JE, Kwiatkowski D, Cook NR, Miletich JP, Chasman DI. Loci related to metabolic-syndrome pathways including LEPR, HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study. Am J Hum Genet 2008, 82(5):1185-1192. 10.1016/j.ajhg.2008.03.015, 2427311, 18439548.
36. Reiner AP, Barber MJ, Guan Y, Ridker PM, Lange LA, Chasman DI, Walston JD, Cooper GM, Jenny NS, Rieder MJ, Durda JP, Smith JD, Novembre J, Tracy RP, Rotter JI, Stephens M, Nickerson DA, Krauss RM. Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein. Am J Hum Genet 2008, 82(5):1193-1201. 10.1016/j.ajhg.2008.03.017, 2427318, 18439552.
37. Crawford DC, Sanders CL, Qin X, Smith JD, Shephard C, Wong M, Witrak L, Rieder MJ, Nickerson DA. Genetic variation is associated with C-reactive protein levels in the Third National Health and Nutrition Examination Survey. Circulation 2006, 114(23):2458-2465. 10.1161/CIRCULATIONAHA.106.615740, 17101857.
38. McQuillan GM, Porter KS, Agelli M, Kington R. Consent for genetic research in a general population: the NHANES experience. Genet Med 2003, 5(1):35-42. 10.1097/00125817-200301000-00006, 12544474.
39. National Center for Health Statistics Laboratory procedures used for NHANES III. Hyattsville, MD 1994, National Center for Health Statistics., http://www.cdc.gov/nchs/data/nhanes/nhanes3/cdrom/nchs/manuals/labman.pdf
40. Gonzalez JR, Carrasco JL, Dudbridge F, Armengol L, Estivill X, Moreno V. Maximizing association statistics over genetic models. Genet Epidemiol 2008, 32(3):246-254. 10.1002/gepi.20299, 18228557.
41. Andreotti F, Porto I, Crea F, Maseri A. Inflammatory gene polymorphisms and ischaemic heart disease: review of population association studies. Heart 2002, 87(2):107-112. 10.1136/heart.87.2.107, 1766990, 11796541.
42. Barbaux S, Tregouet DA, Nicaud V, Poirier O, Perret C, Godefroy T, Francomme C, Combadiere C, Arveiler D, Luc G, Ruidavets JB, Evans AE, Kee F, Morrison C, Tiret L, Brand-Herrmann SM, Cambien F. Polymorphisms in 33 inflammatory genes and risk of myocardial infarction-a system genetics approach. J Mol Med 2007, 85(11):1271-1280. 10.1007/s00109-007-0234-x, 17634906.
43. Visvikis-Siest S, Marteau JB. Genetic variants predisposing to cardiovascular disease. Curr Opin Lipidol 2006, 17(2):139-151. 10.1097/01.mol.0000217895.67444.de, 16531750.
44. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med 2002, 4(2):45-61. 10.1097/00125817-200203000-00002, 11882781.
45. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003, 33(2):177-182. 10.1038/ng1071, 12524541.
46. Arnett DK, Baird AE, Barkley RA, Basson CT, Boerwinkle E, Ganesh SK, Herrington DM, Hong Y, Jaquish C, McDermott DA, O'Donnell CJ. Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: a scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2007, 115(22):2878-2901. 10.1161/CIRCULATIONAHA.107.183679, 17515457.
47. Wang Q, Hunt SC, Xu Q, Chen YE, Province MA, Eckfeldt JH, Pankow JS, Song Q. Association study of CRP gene polymorphisms with serum CRP level and cardiovascular risk in the NHLBI Family Heart Study. Am J Physiol Heart Circ Physiol 2006, 291(6):H2752-2757. 10.1152/ajpheart.01164.2005, 16731635.
48. Zee RY, Ridker PM. Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis 2002, 162(1):217-219. 10.1016/S0021-9150(01)00703-1, 11947917.
49. Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, Peden JF, Erdmann J, Braund P, Engert JC, Bennett D, Coin L, Ashby D, Tzoulaki I, Brown IJ, Mt-Isa S, McCarthy MI, Peltonen L, Freimer NB, Farrall M, Ruokonen A, Hamsten A, Lim N, Froguel P, Waterworth DM, Vollenweider P, Waeber G, Jarvelin MR, Mooser V, Scott J, Hall AS, Schunkert H, Anand SS, Collins R, Samani NJ, Watkins H, Kooner JS. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009, 302(1):37-48. 10.1001/jama.2009.954, 2803020, 19567438.
50. Hamsten A, Iselius L, de Faire U, Blomback M. Genetic and cultural inheritance of plasma fibrinogen concentration. Lancet 1987, 2(8566):988-991. 10.1016/S0140-6736(87)92557-8, 2889959.
51. Folsom AR, Pankow JS, Williams RR, Evans GW, Province MA, Eckfeldt JH. Fibrinogen, plasminogen activator inhibitor-1, and carotid intima-media wall thickness in the NHLBI Family Heart Study. Thromb Haemost 1998, 79(2):400-404.
52. Reinhart WH. Fibrinogen--marker or mediator of vascular disease?. Vasc Med 2003, 8(3):211-216. 10.1191/1358863x03vm494ra, 14989564.
53. Schulz S, Schagdarsurengin U, Suss T, Muller-Werdan U, Werdan K, Glaser C. Relation between the tumor necrosis factor-alpha (TNF-alpha) gene and protein expression, and clinical, biochemical, and genetic markers: age, body mass index and uric acid are independent predictors for an elevated TNF-alpha plasma level in a complex risk model. Eur Cytokine Netw 2004, 15(2):105-111.
54. Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CN, Knott SA, Kolcic I, Polasek O, Graessler J, Wilson JF, Marinaki A, Riches PL, Shu X, Janicijevic B, Smolej-Narancic N, Gorgoni B, Morgan J, Campbell S, Biloglav Z, Barac-Lauc L, Pericic M, Klaric IM, Zgaga L, Skaric-Juric T, Wild SH, Richardson WA, Hohenstein P, Kimber CH, Tenesa A. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008, 40(4):437-442. 10.1038/ng.106, 18327257.
55. Doring A, Gieger C, Mehta D, Gohlke H, Prokisch H, Coassin S, Fischer G, Henke K, Klopp N, Kronenberg F, Paulweber B, Pfeufer A, Rosskopf D, Volzke H, Illig T, Meitinger T, Wichmann HE, Meisinger C. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet 2008, 40(4):430-436. 10.1038/ng.107, 18327256.
56. Li S, Sanna S, Maschio A, Busonero F, Usala G, Mulas A, Lai S, Dei M, Orru M, Albai G, Bandinelli S, Schlessinger D, Lakatta E, Scuteri A, Najjar SS, Guralnik J, Naitza S, Crisponi L, Cao A, Abecasis G, Ferrucci L, Uda M, Chen WM, Nagaraja R. The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genet 2007, 3(11):e194. 10.1371/journal.pgen.0030194, 2065883,2065883, 17997608.
57. Cortese C, Motti C. MTHFR gene polymorphism, homocysteine and cardiovascular disease. Public Health Nutr 2001, 4(2B):493-497. 10.1079/PHN2001159, 11683544.
58. Trabetti E. Homocysteine, MTHFR gene polymorphisms, and cardio-cerebrovascular risk. J Appl Genet 2008, 49(3):267-282.
59. Bautista LE. Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. J Hum Hypertens 2003, 17(4):223-230. 10.1038/sj.jhh.1001537, 12692566.
60. Lazzerini PE, Capecchi PL, Selvi E, Lorenzini S, Bisogno S, Galeazzi M, Laghi Pasini F. Hyperhomocysteinemia, inflammation and autoimmunity. Autoimmun Rev 2007, 6(7):503-509. 10.1016/j.autrev.2007.03.008, 17643940.
61. Stork S, Schouw YT, Grobbee DE, Bots ML. Estrogen, inflammation and cardiovascular risk in women: a critical appraisal. Trends Endocrinol Metab 2004, 15(2):66-72. 10.1016/j.tem.2004.01.005, 15036252.
62. Malarstig A, Buil A, Souto JC, Clarke R, Blanco-Vaca F, Fontcuberta J, Peden J, Andersen M, Silveira A, Barlera S, Seedorf U, Watkins H, Almasy L, Hamsten A, Soria JM. Identification of ZNF366 and PTPRD as novel determinants of plasma homocysteine in a family-based genome-wide association study. Blood 2009, 114(7):1417-1422. 10.1182/blood-2009-04-215269, 19525478.
63. Bis JC, Glazer NL, Psaty BM. Genome-wide association studies of cardiovascular risk factors: design, conduct and interpretation. J Thromb Haemost 2009, 7(Suppl 1):308-311. 10.1111/j.1538-7836.2009.03392.x, 19630823.